Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)

Inclusion Criteria:

* Written informed consent.
* Age between 18 and 70 years.
* Documented by at least 2 out of three mentioned criteria and evidence of non-resectability.

  1. Radiological either CT Scan/US abdomen
  2. Biopsy,
  3. Serum alphafeto protein level
* Multi centric hepatoma or TNM Classification Stage IV.
* Child's class B or C with a Child's score of maximum 11.
* No other active malignancy except localized basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
* Life expectancy of greater then 3 months.
* Current laboratory values must be within the limits listed below:

Haemoglobin \> 8 g/dL WBC \> 4,000/uL Absolute Neutrophil Count \> 1,500/uL Platelets \> 75,000/uL

* ECOG Performance status of \< 2.
* Patients who have received adjuvant or neoadjuvant therapy are eligible. A minimum interval of 4 weeks since last chemotherapy will be required.
* Prior radiotherapy will be allowed if it did not involve a site used to assess response and 4 weeks have elapsed since completion of radiotherapy.

Exclusion Criteria:

* History of allergic reaction to compound chemically related to CAP.
* Concomitant or previous malignancies within five years other than basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix.
* Active, uncontrolled infection. .
* Concurrent medical problems which could limit the life expectancy or the ability of the patient to receive chemotherapy.
* Mental condition that could limit the patient in comprehending the concept of clinical trial or complying with its requirements.
* Brain or leptomeningeal involvement.
* Pre-existing neurotoxicity of \>=grade 2.
* Concomitant radiotherapy, unless localised for bone pain control or palliation.
* Being of reproductive potential and not agreeing to practice an effective contraceptive method.
* Pregnancy or lactation.
* Severe renal impairment with Creatinine clearance \<30ml/minute.
* Documented Cardiomyopathy or severe coronary artery disease, or history of arrhythmias.